Mitochondria-targeting nanomedicine self-assembled from GSH-responsive paclitaxel-ss-berberine conjugate for synergetic cancer treatment with enhanced cytotoxicity
However, synaptic plasticity and memory formation are impaired in GLP-1 receptor knockout mice (118)
Applicable Procedure Codes: 69930, L8614, L8615, L8616, L8617, L8618, L8619, L8627, L8628, V5273
(Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline and other corporate developments
BS: Conceptualization, Data curation, Writing review & editing